News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
February, 2025
February 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
2425262728  
Multimodal approaches combining IO and IO-based therapies for HCC – Digestive Cancers Europe
Feb 4, 2025, 17:18

Multimodal approaches combining IO and IO-based therapies for HCC – Digestive Cancers Europe

Digestive Cancers Europe shared a post on LinkedIn:

“Listen to COR2ED’s final episode of its four-part podcast series for healthcare professionals on hepatocellular carcinoma (HCC), “Intermediate HCC – the evolving role of immunotherapy (IO).”

This episode explores multimodal approaches that combine IO and IO-based therapies with locoregional treatments and highlights the essential role of a multidisciplinary care team.”

IO and IO-based therapies

cancer Digestive Cancers Europe HCC OncoDaily Oncology
Special Coverage
Drugs
Feb 4, 2025, 17:18
Multimodal approaches combining IO and IO-based therapies for HCC - Digestive Cancers Europe
Blog
Feb 4, 2025, 17:17
Ruben Mesa: Excited to participate in “Celebrate Research” across Advocate Health
Blog
Feb 4, 2025, 17:16
Susana Banerjee: Thanks to the 64 participants from 31 countries at the ESMO Resilience Task Force workshop
Science
Feb 4, 2025, 17:11
Akhil Santhosh: 1st chemo-VEGF combo to show PFS and OS in platinum-resistant ovarian cancer
Societies
Feb 4, 2025, 17:10
ESMO is joining the 156th WHO Executive Board Meeting
Blog
Feb 4, 2025, 17:07
Run for the Alliance - Colorectal Cancer Alliance
Science
Feb 4, 2025, 17:07
Giovanni Marchegiani: Can we make a soft pancreas harder to reduce POPF?
Societies
Feb 4, 2025, 17:05
Rallying support to overcome the hurdles of cancer care costs - Canadian Cancer Society
Insight
Feb 4, 2025, 17:04
Hung Trinh: Oncolytic virus and CAR-T cell therapy in solid tumors
Science
Feb 4, 2025, 17:03
Michael Hofman: 18F-CETO for primary aldosteronism
Blog
Feb 4, 2025, 17:02
Axel S. Merseburger: When would you consider HR clinically meaningful in HRR allcomer population?
Science
Feb 4, 2025, 17:00
Bosutinib-Induced Pleural Effusion—Class Effect and Cross-Intolerance to All Tyrosine Kinase Inhibitors by Nikhil Vojjala et al.